Precision Medicine in Active Surveillance for Prostate Cancer: Development of the Canary–Early Detection Research Network Active Surveillance Biopsy Risk Calculator

Men on active surveillance (AS) face repeated biopsies. Most biopsy specimens will not show disease progression or change management. Such biopsies do not contribute to patient management and are potentially morbid and costly. To use a contemporary AS prospective trial to develop a tool to predict AS biopsy outcomes. Biopsy samples (median: 2; range: 2–9 per patient) from 859 men participating in the Canary Prostate Active Surveillance Study and...